Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I (Q35127939)

6 August 2017

1 reference

title

Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I (English)

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(03)13311-9

enzyme replacement therapy

2 January 2024

main subject

0 references

mucopolysaccharidosis I

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12747881

2 January 2024

3

John J Hopwood

1 reference

6 August 2017

Christopher T. Turner

2

object named as

Chris T. Turner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12747881

2 January 2024

5

Doug A. Brooks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12747881

2 January 2024

author name string

Revecca Kakavanos

1

1 reference

6 August 2017

John J. Hopwood

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12747881

2 January 2024

Emil D. Kakkis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12747881

2 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

6 August 2017

10 May 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12747881

full work available at URL

2 January 2024

https://api.elsevier.com/content/article/PII:S0140673603133119?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(03)13311-9

https://api.elsevier.com/content/article/PII:S0140673603133119?httpAccept=text/plain

2 January 2024

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(03)13311-9

2 January 2024

1 reference

6 August 2017

361

1 reference

6 August 2017

1608-1613

1 reference

6 August 2017

9369

1 reference

Prevalence of lysosomal storage disorders

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

1 reference

7 January 2021

Enzyme therapy: problems and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme replacement therapy for murine mucopolysaccharidosis type VII

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme replacement therapy for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme therapy for Gaucher disease: the first 5 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Current issues in enzyme therapy for Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme-replacement therapy in mucopolysaccharidosis I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Structural features of normal and mutant human lysosomal glycoside hydrolases deduced from bioinformatics analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Glycosidase active site mutations in human alpha-L-iduronidase.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913311-9

7 January 2021

FROM CYTASES TO LYSOSOMES

4

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(03)13311-9

2 January 2024

Identifiers

1 reference

6 August 2017

1 reference